In 2015, McKinsey and Co.published their groundbreaking Diversity Matters report with data demonstrating a more diverse leadership team meant a better bottom line. The companies in the top quartile of gender diversity were 15 percent more likely to have financial returns above their national industry median. Several organizations are leading initiatives to raise the profile of women and underrepresented groups within the biopharmaceutical industry implementing strategies to promote upward mobility. Large and small companies alike are rising to the challenge to reframe how the industry thinks and speaks about diversity. This session will focus on practical approaches and successful examples to creating inclusive cultures for development/retention and better aligning organizations with the full measure of talented people available.